Evidence map›Paper›PMID 42517645›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Mitigating Cancer Therapy-Related Cognitive Impairment by Targeted Activation of Undruggable Phosphatase.

Zhimeng Yao, Yuhua Meng, Huanyi Li, Yinhui Jiang, Xiaona Lin, Mengyuan Hu, Qing Liu, Xiaofu Qiu, Hongzheng Ren, Yunlong Pan and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zhimeng YaoDepartment of Urology Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Yuhua MengState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China.
Huanyi LiDepartment of Pharmacy, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Yinhui JiangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China.
Xiaona LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China.
Mengyuan HuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China.
Qing LiuDepartment of Pathology, The First People's Hospital of Foshan, Foshan, Guangdong, China.
Xiaofu QiuDepartment of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.
Hongzheng RenDepartment of Pathology, Gongli Hospital, Naval Medical University, Shanghai, China.
Yunlong PanDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Bin PanDepartment of Urology Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Zexiong GuoDepartment of Urology Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Shuyao ZhangDepartment of Pharmacy, Jinan University Affiliated Guangzhou Red Cross Hospital, Guangzhou, Guangdong, China.
Dianzheng ZhangDepartment of Biomedical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA.
Li YangSchool of Life Sciences, Guangzhou University, Guangzhou, Guangdong, China.
Shegan GaoCollege of Clinical Medicine, Henan Key Laboratory of Cancer Epigenetics, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China.
Weijing DengDepartment of Pharmacy, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Jianfan ChenDepartment of Urology Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China.
Hao ZhangDepartment of Pathology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, China.ORCID https://orcid.org/0000-0002-2860-5912

Funding

Major Project of the Open Joint Fund of the National Clinical Key Specialty Construction of Oncology, The First Affiliated Hospital of Henan University of Science and Technology ZLKFJJ20230104National Natural Science Foundation of China 82303412National Natural Science Foundation of China 82572981Natural Science Foundation of Guangdong Province of China 2025A1515012000Open Project funded by the MOE Key Laboratory of Tumor Molecular Biology 2024 Open Project-202403Science and Technology Projects in Guangzhou 2024A03J1114
6 · The paper itself

Abstract

Cancer therapy-related cognitive impairment (CTRCI) is a debilitating neurotoxic condition adversely impacting cancer patients during and post-cancer treatments. The cancer treatments linked to CTRCI include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Despite CTRCI severely affecting the psychological and social, cognitive functions, and the overall quality of life of cancer survivors, no effective medications are available currently. Our prior studies have indicated hippocampal tyrosine phosphatase protein tyrosine phosphatase receptor type O (PTPRO) as a putative target for CTRCI. However, phosphatase is historically considered undruggable, and delivering drugs across the blood-brain barrier (BBB) is challenging. Here, we developed a novel delivery system using neuron-targeted extracellular vesicles (EVs) engineered with a neuron-specific peptide rabies virus glycoprotein (RVG) to transport a small activating RNA (saRNA) targeting Ptpro (RVG-EVs-saPtpro). We evaluated the stability, dynamic distribution, cytotoxicity, and brain specificity of RVG-EVs-saPtpro in cellular and animal models. A single intravenous injection of RVG-EVs-saPtpro resulted in sustained elevation of PTPRO in the brain for at least 28 days in CTRCI mice. More importantly, RVG-EVs-saPtpro significantly alleviated CTRCI symptoms by enhancing neuronal survival, neurogenesis, and synaptic plasticity. These findings highlight the potential of RVG-EVs-saPtpro system for targeted treatment of CTRCI.

Indexed as

cognitive dysfunctionexosome‐based delivery systemlife quality of cancer survivorssaRNA delivery to brainsmall RNA activationtargeted therapy for CTRCItyrosine phosphatase

Identifiers

PMID42517645
PMCPMC13410807

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.